Clinical trial NCT03592693: Vitamin C, Hydrocortisone and Thiamine for Septic Shock
Official title: A Randomized, Double Blind, Placebo-Controlled Trial to Investigate the Effect of Vitamin C, Hydrocortisone and Thiamine on the Outcome of Patients with Septic Shock
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Shock, Septic
Keywords: Shock, Septic
Vitamin C
Hydrocortisone
Lead sponsor: University of Athens
Sponsor class: OTHER
Collaborators: name: General Hospital of Nikaia "Saint Panteleimon"
name: Naval Hospital, Athens
First posted: 2018-07-19
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, multicenter, parallel group, placebo-controlled \[Vitamin c plus hydrocortisone or placebo plus placebo
Primary purpose: TREATMENT

Brief summary: Prior data has shown that both corticosteroids and vitamin C reduce the activation of nuclear factor ƘB (NFƘB), thereby ultimately attenuating the systemic inflammatory response to sepsis/septic shock and augmenting the responsiveness to vasopressors. Therefore, the current investigators hypothesized that the combined use of vitamin C and stress-dose hydrocortisone may improve the outcomes of patients with septic shock. The investigators intend to perform a randomized, multicenter, parallel group, double-blind, placebo-controlled trial of vitamin C plus stress-dose hydrocortisone or placebo plus placebo for a total of four days after randomization of patients fulfilling the current consensus criteria for septic shock. The primary outcome will be hospital mortality, whereas the scondary outcomes will include 60-day, 28-day mortality, time to vasopressor cessation, procalcitonin clearance and change in the Sequential Organ Failure Assessment score over the first 4 days after randomization, neurologic failure-free days, and length of stay in the intensive care unit (ICU) and the hospital. Target enrollment will be 400 patients.

Detailed description: Background and Significance:

The global burden of sepsis is substantial with an estimated 15 to 19 million cases per year; the vast majority of these cases occur in low income countries. With more timely diagnosis and improvement in supportive care the 28-day mortality from sepsis in high income countries has declined to about 25%, however, the mortality from septic shock remains as high as 45%. Moreover, the mortality from sepsis and septic shock in low income countries is reported to be as high as 60%. Over the last 3 decades over 100 phase II and phase III clinical trials have been performed testing various novel pharmacologic agents and therapeutic interventions in an attempt to improve the outcome of patients with sepsis and septic shock; all of these studies have failed to show an improvement in patient outcomes. A large body of experimental data has demonstrated that both corticosteroids and intravenous vitamin C reduce activation of nuclear factor ƘB (NFƘB) and attenuatethe release of pro-inflammatory mediators, reduce the endothelial injury characteristic of sepsis (thereby reducing endothelial permeability and improving macrocirculatory flow), augment the release of endogenous catecholamines, and enhance vasopressor responsiveness. In addition, recent evidence suggests that thiamine may be neuroprotective in severe shock states.

Specific Aims of the Study:

The aim of this study is to determine the effect of the combination of intravenous vitamin C, hydrocortisone and thiamine on the clinical course and outcome of patients with septic shock.

Study Design:

This study will be performed at 4 tertiary Greek Intensive Care Units (ICUs). All patients admitted to any ICU of the participating hospitals with the primary diagnosis of severe sepsis or septic shock will be screened for inclusion. The diagnosis of septic shock will be based on recent consensus criteria.

ICU management protocol:

All septic patients enrolled in this study will be managed by a standardized approach which will comprise:

i. Empirical treatment with broad spectrum antibiotics, which will be subsequently deescalated according to microbiological data and clinical improvement ii. A conservative strategy of fluid and vasopressor management. iii. A lung-protective ventilation strategy. iv. Limited use of sedative agents (dexmedetomidine will be the preferred agent) v. Enteral nutrition with a whey-based formula using an intermittent bolus protocol which will preferrably be started within 24 hours of ICU admission.

vi. Prophylaxis against deep venous thrombosis prophylaxis with both enoxaparin (or heparin in patients with a calculated creatinine clearance \< 30ml/min) and sequential compression.

vii. Permissive hyperglycemia (blood glucose of 150-200 mg/dL).

Vitamin C, Hydrocortisone and Thiamine dosing protocol and randomization

This is a double-blind placebo controlled study. Only the pharmacist will be aware of the treatment allocation. Patients will be randomized to receive either vitamin C/hydrocortisone or placebo plus placebo using a random number table provided to the dispensing pharmacists. Each patient will be allocated a unique participant ID which will be linked to the randomization sequence. Only the dispensing pharmacists will have a record of the participant ID and randomization sequence. The vitamin C/placebo and hydrocortisone/placebo will be formulated as follows:

Vitamin C: 1500 mg of vitamin C will be dissolved in a 50 or 100 mL bag of normal saline and will be infused over 1 hour. The dosing schedule will be 1500 mg every 6 hours for 4 days or until discharge from the ICU.

Vitamin C placebo will consist of an identical bag of 50 or 100 mL normal saline (but with no vitamin C) and will be labeled vitamin C. Placebo will be infused over 1 hour as per the infusion instructions of the active vitamin.

Hydrocortisone: Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.

Optional dosing strategy: Hydrocortisone 50 mg bolus, followed by a 24-hour continuous infusion of 200 mg (in 50 or 100 ml normal saline) for 4 days.

Hydrocortisone placebo will be provided as an identical syringe/50 or 100 mL bag of normal saline.

Thiamine: As a high percentage of septic patients have been shown to be thiamine deficient, patients will receive intravenous thiamine 200mg q 12 hourly for 4 days or until ICU discharge. Thiamine is also a cofactor for the metabolism of oxalate (a byproduct of vitamin C metabolism), with thiamine deficiency increasing oxalate levels. To simplify the study, both the intervention and control group will receive thiamine.

Eligibility criteria: Inclusion Criteria:

* i. Diagnosis of septic shock within 12 hours of admission to the ICU

Exclusion Criteria:

* i. Age \< 18 years ii. Pregnant iii. Patients with an end-stage underlying disease who are unlikely to survive to hospital discharge iv. Patients with acquired immunodeficiency syndrome and a CD4 count of \< 50 per microliter v. Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency. vi. Patients with septic shock transferred from another hospital vii. Patients with septic shock for more than 12 hours viii. Patients who require off-label treatment with corticosteroids for an indication other than sepsis ix. Lack of written, informed consent

Primary outcomes:
measure: Hospital Mortality
timeFrame: 90 days
Secondary outcomes:
measure: 60-day mortality
timeFrame: 60 days
measure: 28-day mortality
timeFrame: 28 days
measure: Procalcitonin (PCT) clearance .
timeFrame: 4 days
measure: Delta Sequential Organ Failure Assessment (SOFA) score
timeFrame: 4 days
measure: Neurologic failure-free days (defined as daily follow-up Glasgow Coma Score >9) within the first 28 days of follow-up
timeFrame: 28 days
measure: Intensive Care Unit (ICU) mortality
timeFrame: 90 days
measure: ICU free days to day 28.
timeFrame: 28 days
measure: ICU length of stay
timeFrame: 90 days
measure: Hospital length of stay
timeFrame: 90 days
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Evaggelismos General Hospital
state: Attica
city: Piraeus
country: Greece
facility: General Hospital of Nikaia Saint Panteleimon
state: Attica
Study officials:
affiliation: National and Kapodestrian University of Athens, Greece
name: Anastasia Kotanidou, MD, PHD, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: National and Kapodestrian University of Athens, Greece
name: Spyros D Mentzelopoulos, MD, PHD, Associate Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: National and Kapodestrian University of Athens, Greece
name: Stylianos Orfanos, MD, PHD, Professor
role: STUDY_DIRECTOR
affiliation: National and Kapodestrian University of Athens, Greece
name: Spyros G Zakynthinos, MD, PHD, Professor
role: STUDY_CHAIR
References:
citation: Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289.
citation: Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun;151(6):1229-1238. doi: 10.1016/j.chest.2016.11.036. Epub 2016 Dec 6.